This is a pharmacokinetic study for TGRX-326 on mass balance to evaluate distribution, metabolism and excretion of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborator:
The First Affiliated Hospital of Soochow University